Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2

被引：86
|
作者：
Yu, Fei [1 ]
Xiang, Rong [1 ]
Deng, Xiaoqian [1 ]
Wang, Lili [2 ]
Yu, Zhengsen [1 ]
Tian, Shijun [1 ]
Liang, Ruiying [1 ]
Li, Yanbai [1 ]
Ying, Tianlei [3 ]
Jiang, Shibo [3 ]
机构：
[1] Hebei Agr Univ, Coll Life Sci, Baoding, Peoples R China
[2] Hebei Agr Univ, Res Ctr Chinese Jujube, Baoding, Peoples R China
[3] Fudan Univ, Sch Basic Med Sci, CAMS, Key Lab Med Mol Virol,MOE,NHC, Shanghai, Peoples R China
来源：
SIGNAL TRANSDUCTION AND TARGETED THERAPY | 2020年 / 5卷 / 01期
基金：
中国国家自然科学基金;
关键词：
ACUTE RESPIRATORY SYNDROME; CORONAVIRUS SPIKE PROTEIN; POTENT NEUTRALIZATION; VIRUS; IMMUNOPROPHYLAXIS; IDENTIFICATION; GENERATION; EPITOPES; FRAGMENT; VACCINE;
D O I：
10.1038/s41392-020-00318-0
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The outbreaks of severe acute respiratory syndrome (SARS) and Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV and SARS-CoV-2, respectively, have posed severe threats to global public health and the economy. Treatment and prevention of these viral diseases call for the research and development of human neutralizing monoclonal antibodies (NMAbs). Scientists have screened neutralizing antibodies using the virus receptor-binding domain (RBD) as an antigen, indicating that RBD contains multiple conformational neutralizing epitopes, which are the main structural domains for inducing neutralizing antibodies and T-cell immune responses. This review summarizes the structure and function of RBD and RBD-specific NMAbs against SARS-CoV and SARS-CoV-2 currently under development.
引用
收藏
页数：12
相关论文
共 50 条
  • [1] Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies
    Yuan, Meng
    Liu, Hejun
    Wu, Nicholas C.
    Wilson, Ian A.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2021, 538 : 192 - 203
  • [2] Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2
    Tai, Wanbo
    Zhang, Xiujuan
    He, Yuxian
    Jiang, Shibo
    Du, Lanying
    ANTIVIRAL RESEARCH, 2020, 179
  • [3] SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1
    Law, John Lok Man
    Logan, Michael
    Joyce, Michael A.
    Landi, Abdolamir
    Hockman, Darren
    Crawford, Kevin
    Johnson, Janelle
    LaChance, Gerald
    Saffran, Holly A.
    Shields, Justin
    Hobart, Eve
    Brassard, Raelynn
    Arutyunova, Elena
    Pabbaraju, Kanti
    Croxen, Matthew
    Tipples, Graham
    Lemieux, M. Joanne
    Tyrrell, D. Lorne
    Houghton, Michael
    VACCINE, 2021, 39 (40) : 5769 - 5779
  • [4] Neutralizing antibody response elicited by SARS-CoV-2 receptor-binding domain
    Huang, Ping-Han
    Tsai, Hsiao-Han
    Liao, Bo-Hung
    Lin, Yi-Ling
    Jan, Jia-Tsrong
    Tao, Mi-Hua
    Chou, Yu-Chi
    Hu, Che-Ming Jack
    Chen, Hui-Wen
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (03) : 654 - 655
  • [5] On the interactions of the receptor-binding domain of SARS-CoV-1 and SARS-CoV-2 spike proteins with monoclonal antibodies and the receptor ACE2
    Giron, Carolina Correa
    Laaksonen, Aatto
    Barroso da Silva, Fernando L.
    VIRUS RESEARCH, 2020, 285
  • [6] Neutralization of SARS-CoV-2 requires antibodies against conformational receptor-binding domain epitopes
    Gattinger, Pia
    Niespodziana, Katarzyna
    Stiasny, Karin
    Sahanic, Sabina
    Tulaeva, Inna
    Borochova, Kristina
    Dorofeeva, Yulia
    Schlederer, Thomas
    Sonnweber, Thomas
    Hofer, Gerhard
    Kiss, Renata
    Kratzer, Bernhard
    Trapin, Doris
    Tauber, Peter A.
    Rottal, Arno
    Kormoczi, Ulrike
    Feichter, Melanie
    Weber, Milena
    Focke-Tejkl, Margarete
    Loffler-Ragg, Judith
    Muhl, Bernhard
    Kropfmuller, Anna
    Keller, Walter
    Stolz, Frank
    Henning, Rainer
    Tancevski, Ivan
    Puchhammer-Stockl, Elisabeth
    Pickl, Winfried F.
    Valenta, Rudolf
    ALLERGY, 2022, 77 (01) : 230 - 242
  • [7] Unraveling the stability landscape of mutations in the SARS-CoV-2 receptor-binding domain
    Smaoui, Mohamed Raef
    Yahyaoui, Hamdi
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [8] Attenuated Influenza Virions Expressing the SARS-CoV-2 Receptor-Binding Domain Induce Neutralizing Antibodies in Mice
    Loes, Andrea N.
    Gentles, Lauren E.
    Greaney, Allison J.
    Crawford, Katharine H. D.
    Bloom, Jesse D.
    VIRUSES-BASEL, 2020, 12 (09):
  • [9] Antibodies to neutralising epitopes synergistically block the interaction of the receptor-binding domain of SARS-CoV-2 to ACE 2
    Pandey, Manisha
    Ozberk, Victoria
    Eskandari, Sharareh
    Shalash, Ahmed O.
    Joyce, Michael A.
    Saffran, Holly A.
    Day, Christopher J.
    Lepletier, Ailin
    Spillings, Belinda L.
    Mills, Jamie-Lee
    Calcutt, Ainslie
    Fan, Fan
    Williams, James T.
    Stanisic, Danielle, I
    Hattingh, Laetitia
    Gerrard, John
    Skwarczynski, Mariusz
    Mak, Johnson
    Jennings, Michael P.
    Toth, Istvan
    Tyrrell, D. Lorne
    Good, Michael F.
    CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2021, 10 (03)
  • [10] Recombinant Mycobacterium paragordonae Expressing SARS-CoV-2 Receptor-Binding Domain as a Vaccine Candidate Against SARS-CoV-2 Infections
    Kim, Byoung-Jun
    Jeong, Hyein
    Seo, Hyejun
    Lee, Mi-Hyun
    Shin, Hyun Mu
    Kim, Bum-Joon
    FRONTIERS IN IMMUNOLOGY, 2021, 12
12345